Kodiak Sciences (NASDAQ:KOD) Stock Jumps 6.3% – Time to Buy?

Kodiak Sciences Inc. (NASDAQ:KOD) was up 6.3% during mid-day trading on Thursday. The company traded as high as $33.40 and last traded at $33.5190. 762,167 shares were traded during trading, a decline of 8% from the average session volume of 831,858 shares. The stock had previously closed at $31.52.

Key Kodiak Sciences News

Here are the key news stories impacting Kodiak Sciences this week:

• Positive Sentiment: Kodiak announced that it will report topline results on September 28 from the pivotal Phase 3 DAYBREAK study evaluating Zenkuda (tarcocimab tedromer) and KSI-501 (tabirafusp alfa tedromer) in wet age-related macular degeneration. The readout is the primary near-term catalyst for KOD because successful results could support regulatory filings and materially improve the company’s commercial outlook. Kodiak Sciences to Present Topline Results on September 28, 2026 from DAYBREAK Pivotal Phase 3 Study
• Positive Sentiment: Market coverage highlights strong investor anticipation ahead of the DAYBREAK results, helping explain the recent surge in Kodiak’s shares. However, the move also raises the risk of a sharp reaction in either direction once the data are released. Kodiak Sciences Shares Surge Ahead of Phase 3 Readout
• Neutral Sentiment: Goldman Sachs initiated coverage with a Neutral rating and a $36 price target, implying moderate upside from the referenced price but signaling limited conviction before the clinical readout.
• Neutral Sentiment: Reported short-interest data showed zero shares sold short and a zero-day short-interest ratio, suggesting short covering is unlikely to be a meaningful driver of the recent move.
• Negative Sentiment: Some coverage argues Kodiak looks overvalued after its substantial rally. With the company still precommercial and previously reporting a quarterly EPS loss below consensus, disappointing DAYBREAK data could trigger significant downside. Kodiak Sciences Stock Looks Overvalued After Its 15x Run

Analysts Set New Price Targets

Several research analysts have recently weighed in on the stock. Wall Street Zen cut shares of Kodiak Sciences from a “sell” rating to a “strong sell” rating in a report on Saturday. The Goldman Sachs Group began coverage on shares of Kodiak Sciences in a report on Thursday. They issued a “neutral” rating and a $36.00 target price on the stock. JPMorgan Chase & Co. lifted their target price on shares of Kodiak Sciences from $56.00 to $66.00 and gave the stock an “overweight” rating in a research report on Monday, August 3rd. HC Wainwright reiterated a “buy” rating and set a $58.00 target price on shares of Kodiak Sciences in a research note on Thursday, September 17th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kodiak Sciences in a report on Friday, July 10th. Five investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Kodiak Sciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $56.83.

Kodiak Sciences Stock Down 2.6%

The business has a 50 day moving average price of $38.31 and a two-hundred day moving average price of $37.26. The stock has a market cap of $2.03 billion, a P/E ratio of -7.72 and a beta of 2.18.

Kodiak Sciences (NASDAQ:KOD) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($1.05) earnings per share for the quarter, missing the consensus estimate of ($0.96) by ($0.09). On average, research analysts forecast that Kodiak Sciences Inc. will post -3.89 earnings per share for the current year.

Institutional Investors Weigh In On Kodiak Sciences

Hedge funds have recently made changes to their positions in the company. Engineers Gate Manager LP increased its stake in Kodiak Sciences by 145.8% in the 2nd quarter. Engineers Gate Manager LP now owns 29,537 shares of the company’s stock worth $1,151,000 after acquiring an additional 17,520 shares during the last quarter. Squarepoint Ops LLC grew its holdings in shares of Kodiak Sciences by 112.6% in the second quarter. Squarepoint Ops LLC now owns 151,098 shares of the company’s stock valued at $5,887,000 after purchasing an additional 80,042 shares in the last quarter. Arizona State Retirement System grew its holdings in shares of Kodiak Sciences by 6.9% in the second quarter. Arizona State Retirement System now owns 8,533 shares of the company’s stock valued at $332,000 after purchasing an additional 554 shares in the last quarter. Hsbc Holdings PLC bought a new stake in Kodiak Sciences in the second quarter worth $232,000. Finally, Wellington Management Group LLP raised its stake in Kodiak Sciences by 81.9% during the second quarter. Wellington Management Group LLP now owns 793,613 shares of the company’s stock valued at $30,919,000 after purchasing an additional 357,284 shares in the last quarter. 89.06% of the stock is currently owned by hedge funds and other institutional investors.

About Kodiak Sciences

Kodiak Sciences Inc (NASDAQ: KOD) is a biopharmaceutical company focused on developing therapies for retinal diseases and other conditions affecting the eye. The company’s research is centered on antibody biopolymer conjugates, a technology designed to extend the duration of action of biologic medicines in ocular tissues and potentially reduce the frequency of administration.

Its lead development program has been tarcocimab tedromer, also known as KSI-301, an anti-vascular endothelial growth factor (VEGF) therapy investigated for retinal vascular diseases, including diabetic macular edema, diabetic retinopathy and neovascular age-related macular degeneration.